Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Recruiting · NCT06645678 · Registry updated 2025-12-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2025-12-03 | NCT06645678 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| YOUNGIL KOH | 1 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center, University of Ulsan College of Medicine | Seoul | South Korea | 2 |
| Chonnam National University Hwasun Hospital | Hwasun | South Korea | 12 |
| National University Hospital (NUH) | Singapore | Singapore | 1 |
| Samsung Medical Center, Sungkyunkwan University School of Medicine | Seoul | South Korea | 2 |
| Seoul National University Hospital | Seoul | South Korea | 183 |
| Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea | Seoul | South Korea | 1 |
| Singhealth Duke NUS blood cancer center | Singapore | Singapore | 1 |